Capital World Investors Has $328.31 Million Holdings in Natera, Inc. $NTRA

Capital World Investors raised its position in Natera, Inc. (NASDAQ:NTRA) by 1.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,433,094 shares of the medical research company’s stock after acquiring an additional 20,371 shares during the period. Capital World Investors owned approximately 1.04% of Natera worth $328,308,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC bought a new position in shares of Natera in the fourth quarter valued at approximately $41,000. Horizon Investments LLC bought a new stake in Natera during the third quarter worth $32,000. TD Waterhouse Canada Inc. bought a new stake in Natera during the fourth quarter worth $62,000. Sound Income Strategies LLC lifted its holdings in Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the period. Finally, Fifth Third Bancorp lifted its holdings in Natera by 123.4% during the fourth quarter. Fifth Third Bancorp now owns 324 shares of the medical research company’s stock worth $74,000 after acquiring an additional 179 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NTRA stock opened at $213.47 on Tuesday. The company has a market cap of $30.57 billion, a P/E ratio of -130.96 and a beta of 1.56. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The stock’s fifty day moving average price is $204.53 and its 200-day moving average price is $216.13.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roelof Botha sold 78,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. The trade was a 6.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 148,500 shares of company stock worth $32,274,898. Company insiders own 5.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NTRA shares. JPMorgan Chase & Co. boosted their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Wolfe Research initiated coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. Finally, BTIG Research lowered their price target on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.12.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.